Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Raloxifene |
Synonyms | |
Therapy Description |
Evista (raloxifene) is a selective estrogen receptor modulator (SERM), which can act as an estrogen antagonist and is FDA approved for breast cancer (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Raloxifene | Evista | LY-139481 | Hormone - Anti-estrogens 29 | Evista (raloxifene) is a selective estrogen receptor modulator (SERM), which can act as an estrogen antagonist and is FDA approved for breast cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03147196 | Phase II | Bicalutamide + Raloxifene Raloxifene Bicalutamide | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Withdrawn | 0 |